gdc-0917
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01226277)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Inhibitor of apoptosis protein 3ANTAGONIST
XIAP antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1sc(-c2ncco2)nc1-c1ccccc1)C1CCCCC1- Mol. weight
- 564.71 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297282 ↗
Also known as
- cudc-427
- cudc-427
- gdc-0917
- gdc-0917
- gdc-0917
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01908413 | Phase 1 | Jul 1, 2013 | Curis |
| NCT01226277 | Phase 1 | Oct 1, 2010 | Genentech |
Showing 2 of 2 trials
Page 1 / 1